Loading...
Longeveron Q1 2025 Earnings Report
Longeveron reported a decrease in revenue and an increase in net loss for Q1 2025, primarily due to decreased participant demand for their Bahamas Registry Trial, partially offset by increased manufacturing services contract revenue.
Key Takeaways
Longeveron Inc. experienced a challenging first quarter in 2025, with total revenues decreasing to $381,000 from $548,000 in the prior year. The company's net loss widened to $5,011,000, compared to $4,058,000 in Q1 2024, driven by increased operating expenses, particularly in general and administrative costs and research and development. The decrease in revenue was primarily attributed to lower participant demand for the Bahamas Registry Trial, despite an increase in contract manufacturing revenue.
Total revenues decreased by 30% to $381,000 in Q1 2025 from $548,000 in Q1 2024.
Net loss increased by 23% to $5,011,000 in Q1 2025 from $4,058,000 in Q1 2024.
General and administrative expenses rose by 34% to $2,941,000, mainly due to increased personnel and equity-based compensation costs.
Research and development expenses increased by 13% to $2,515,000, driven by higher personnel and patent-related costs, despite a decrease in clinical trial expenses.
Revenue by Segment
Forward Guidance
Longeveron anticipates increased operating expenses and capital expenditure requirements throughout calendar 2025 due to BLA enabling activities for HLHS and manufacturing readiness. The company intends to seek additional financing and non-dilutive funding options to support these initiatives.
Positive Outlook
- Successful Type C meeting with the FDA in August 2024 regarding the HLHS regulatory pathway.
- Anticipated potential BLA filing with the FDA in 2026 if the current ELPIS II trial in HLHS is successful.
- Focus on seeking partnership opportunities and/or non-dilutive funding for the Alzheimer's disease program.
- Proposed single, pivotal, seamless adaptive Phase 2/3 clinical trial for Alzheimer's disease.
- FDA granted request for a Type B meeting on March 20, 2025, supporting the advancement of Lomecel-B™ as a potential treatment for mild AD.
Challenges Ahead
- Current cash and cash equivalents are only anticipated to fund operations late into the third quarter of 2025.
- Operating expenses and capital expenditure requirements are expected to increase throughout calendar 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...